Home » Stocks » AMAG

AMAG Pharmaceuticals, Inc. (AMAG)

Nov 16, 2020 - AMAG was delisted (reason: acquired by Covis Group)
Stock Price: $13.75 USD 0.00 (0.00%)
Updated Nov 16, 2021 4:00 PM EST
Market Cap 477.47M
Revenue (ttm) 303.03M
Net Income (ttm) -229.17M
Shares Out 34.48M
EPS (ttm) -6.77
PE Ratio n/a
Forward PE 30.49
Dividend n/a
Dividend Yield n/a
Trading Day Nov 16, 2021
Last Price $13.75
Previous Close $13.75
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 13.75 - 13.76
Day's Volume 0
52-Week Range 4.41 - 13.80

News

Hide News
PRNewsWire - 3 months ago

NEW YORK, Nov. 4, 2020 /PRNewswire/ -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the ...

Zacks Investment Research - 4 months ago

AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 4 months ago

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the...

PRNewsWire - 4 months ago

LUXEMBOURG and ZUG, Switzerland, Oct. 15, 2020 /PRNewswire/ -- Covis Group S.à r.l. ("Covis") announced the commencement of a cash tender offer to purchase all of the outstanding shares of com...

GlobeNewsWire - 4 months ago

WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it has formally requested a public hearing in response to the U.S. Food and Dru...

PRNewsWire - 4 months ago

NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New...

Business Wire - 4 months ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of AMAG Pha...

PRNewsWire - 4 months ago

NEW YORK, Oct. 5, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) concerning potential violations of the f...

GlobeNewsWire - 4 months ago

WALTHAM, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it received a notice from the U.S. Food and Drug Administration (FDA) that the ...

Zacks Investment Research - 4 months ago

AMAG (AMAG) is set to be acquired by Covis Group for approximately $647 million.

PRNewsWire - 5 months ago

NEW YORK, Oct. 2, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of AMAG Pharmaceuticals, Inc. ("A...

PRNewsWire - 5 months ago

NEW YORK, Oct. 2, 2020 /PRNewswire/ -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the ...

PRNewsWire - 5 months ago

NEW YORK, Oct. 2, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and its board of directors concerning t...

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) to Covis Group S.à r.l. (“Covis”)...

The Motley Fool - 5 months ago

The company is being gobbled up by another drugmaker.

Newsfile Corp - 5 months ago

New York, New York--(Newsfile Corp. - October 1, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased AMAG Pharmaceuticals, Inc. (...

GlobeNewsWire - 5 months ago

Addition of AMAG’s category leading treatments positions Covis to become a global market leader of therapeutic solutions for life-threatening conditions and chronic illnesses

GlobeNewsWire - 5 months ago

WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Scott Myers, Chief Executive Officer, and Brian Piekos, Chief Financial Offi...

Zacks Investment Research - 5 months ago

AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 6 months ago

AMAG Pharmaceuticals (AMAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 6 months ago

AMAG Pharmaceuticals, Inc. (AMAG) CEO Scott Myers on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.

Zacks Investment Research - 6 months ago

AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of 16.67% and -6.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the s...

GlobeNewsWire - 6 months ago

Financial guidance reissued to include EBITDA-positive projection for second-half 2020

Zacks Investment Research - 7 months ago

AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

Vyleesi® returned to Palatin Technologies

Benzinga - 7 months ago

AMAG Pharmaceuticals (NASDAQ: AMAG) shares are trading lower after the company announced it has entered into an exclusive licensing agreement with B.V.

GlobeNewsWire - 7 months ago

Agreement provides AMAG with $30 million upfront payment and eligibility to receive up to $260 million in development and commercial milestones in addition to sales royalties  

GlobeNewsWire - 7 months ago

Data from two Phase 2 randomized, placebo-controlled, dose-ranging studies using ciraparantag demonstrate efficacy and safety in the reversal of apixaban and rivaroxaban Data from two Phase 2 ...

GlobeNewsWire - 8 months ago

Company initiates CFO & COO succession plan; appoints internal seasoned finance leader as interim CFO

Zacks Investment Research - 8 months ago

AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 9 months ago

Transaction allows AMAG to advance its strategic focus on Feraheme, Makena and its pipeline, consistent with previously announced plans

Zacks Investment Research - 9 months ago

AMAG Pharmaceuticals' (AMAG) loss narrows year over year while sales top estimates in the first quarter of 2020. The company scraps 2020 outlook due to the plaguing pandemic effect.

Seeking Alpha - 9 months ago

AMAG Pharma: Shedding Lackadaisical Segments And Management - Becoming A Focused, Undervalued Pure Play

Seeking Alpha - 9 months ago

AMAG Pharmaceuticals, Inc. (AMAG) CEO Scott Myers on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -4000.00% and 5.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for th...

The Motley Fool - 9 months ago

Nearly one year after the launch of a drug that increases women's sexual desire, this company's efforts to market it have faltered.

Zacks Investment Research - 10 months ago

AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 10 months ago

WALTHAM, Mass., April 16, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today provided an update regarding the potential impact of COVID-19 on the company. AMAG is commi...

Zacks Investment Research - 10 months ago

AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 11 months ago

Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.

Other stocks mentioned: CPIX, MIST
Zacks Investment Research - 11 months ago

AMAG (AMAG) plans to divest two of its women healthcare drugs, Intrarosa and Vyleesi. Its marketed drug, Feraheme, achieves record sales in 2019.

Zacks Investment Research - 11 months ago

AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.

The Motley Fool - 11 months ago

The drugmaker had more bad news than good news in its latest quarterly update.

Seeking Alpha - 11 months ago

AMAG Pharmaceuticals, Inc. (AMAG) CEO Bill Heiden on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -2.94% and 1.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for th...

GlobeNewsWire - 11 months ago

Conference call scheduled for 8:00 a.m. EST today Conference call scheduled for 8:00 a.m. EST today

GlobeNewsWire - 11 months ago

WALTHAM, Mass., March 04, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced changes to its medical development organization. Effective March 31, 2020, Julie ...

Zacks Investment Research - 1 year ago

AMAG is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

Zacks Investment Research - 1 year ago

AMAG Pharmaceuticals (AMAG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

About AMAG

AMAG Pharmaceuticals, a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of prete... [Read more...]

Industry
Biotechnology
Founded
1981
CEO
Scott D. Myers
Employees
440
Stock Exchange
NASDAQ
Ticker Symbol
AMAG
Full Company Profile

Financial Performance

In 2019, AMAG's revenue was $326.55 million, a decrease of -30.82% compared to the previous year's $472.05 million. Losses were -$467.66 million, 582.7% more than in 2018.

Financial Statements